Modulating Metabolic Gene Expression with Small Molecule Agonists for LRH-1
Modulating Metabolic Gene Expression with Small Molecule Agonists for LRH-1
批准号:
9911759
负责人:
Elizabeth Joy Millings
金额:
$5.43万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-04-01 至 2021-01-15
关键词:
AddressAdultAffectAgonistBindingBiochemistryBlood GlucoseBody WeightCell LineCellsCharacteristicsControl GroupsCountryDataDevelopmentDietDiseaseDisease modelDoseEducationEducational process of instructingEffectivenessEndocrineEnsureEnvironmentExhibitsFatty LiverFatty acid glycerol estersFellowshipGene ActivationGene ExpressionGene Expression RegulationGene TargetingGenesGenetic TranscriptionGoalsHepaticHepatocyteHigh Fat DietHomeostasisHomologous GeneHumanIn VitroInsulin ResistanceKnockout MiceLecithinLigand BindingLigandsLipidsLiverLiver diseasesMeasuresMediatingMetabolicMetabolic DiseasesMetabolic PathwayMetabolic dysfunctionMetabolic syndromeMethodsMusNR5A2 geneNatureNon-Insulin-Dependent Diabetes MellitusNuclear Orphan ReceptorNuclear ReceptorsObese MiceObesityOperative Surgical ProceduresPathway AnalysisPathway interactionsPharmaceutical PreparationsPharmacologyPhospholipidsPhysiologyPlayPopulationReceptor ActivationReceptor GeneRegulationResearchResearch PersonnelScienceSeriesSerumSignal PathwaySignal TransductionSolubilitySpecificityStructureSymptomsTestingTherapeuticTrainingTransgenic MiceUniversitiesbaseblood glucose regulationchromatin immunoprecipitationdesigneffectiveness testingglucose metabolismglucose toleranceimprovedin vivoin vivo Modelinsulin sensitivityliver functionmedical schoolsmouse modelnon-alcoholic fatty liver diseasenovelprogramspromoterreceptorsmall moleculetherapeutic targettranscriptome sequencingtranscriptomics
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract
Liver homolog receptor (LRH-1) is a nuclear receptor that plays a key role in hepatic metabolic signaling.
Targeting LRH-1 in the context of obesity results in marked improvements in insulin sensitivity and hepatic lipid
homeostasis. This suggests that LRH-1 could be an important therapeutic target in metabolic diseases such as
Type 2 diabetes and fatty liver disease.
Using structure-based design, novel LRH-1 modulators have been developed that potently activate LRH-1 both
in vitro and in vivo. However, it remains unknown how activating LRH-1 with synthetic agonists will modulate
gene expression and metabolic signaling pathways. In Aim 1, RNA-seq and ChIP-seq methods will be used to
examine how synthetic agonists with different binding mechanisms can alternately regulate LRH-1 target
genes in primary human hepatocytes. In Aim 2, diet-induced obese mice will be dosed with a synthetic LRH-1
agonist to treat their metabolic dysfunction. Parameters of lipid and glucose homeostasis will be measured to
elucidate the effectiveness of an LRH-1 agonist in reversing metabolic symptoms. To ensure agonist specificity
for LRH-1, LRH-1 KO mice will be used as experimental controls. As one of the first studies to target LRH-1 in
vivo with synthetic agonists, this research will provide vital information about the therapeutic potential of
targeting LRH-1 to treat metabolic diseases.
Fellowship training will be conducted in the departments of Biochemistry and Surgery at Emory University
School of Medicine and will include hands-on training in transcriptomic sequencing, lipidomics, and mouse
transgenics and physiology. Training will take place in the stimulating intellectual environment at Emory
University and draw upon the expertise of several collaborators and research cores. The IRACDA Fellowships
in Research and Science Teaching (FIRST) program and the Office of Postdoctoral Education will also provide
additional teaching and professional development opportunities. In summary, the pioneering research
described here in combination with the exceptional training environment will ensure the successful
development of this applicant into an independent research investigator.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金